(Total Views: 338)
Posted On: 09/09/2019 3:51:19 PM
Post# of 88
NetworkNewsBreaks – Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) Receives Health Canada Approval to Bring Moncton Facility’s Annualized Licensed Capacity to 76,000 kg Target
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc., a leading licensed producer of cannabis, today announced its receipt of Health Canada approval, effective September 6, 2019, for the licensing of 17 additional cultivation rooms under the Cannabis Regulations. According to the update, the new cultivation rooms represent an increased target production capacity of approximately 15,000 kg per year. These are the company’s first 17 rooms licensed within its Phase 4B expansion and now brings its Moncton facility’s annualized licensed capacity to a target of 76,000 kg. “Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date,” Organigram CEO Greg Engel said in the news release. “Our Phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc., a leading licensed producer of cannabis, today announced its receipt of Health Canada approval, effective September 6, 2019, for the licensing of 17 additional cultivation rooms under the Cannabis Regulations. According to the update, the new cultivation rooms represent an increased target production capacity of approximately 15,000 kg per year. These are the company’s first 17 rooms licensed within its Phase 4B expansion and now brings its Moncton facility’s annualized licensed capacity to a target of 76,000 kg. “Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date,” Organigram CEO Greg Engel said in the news release. “Our Phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
